Oruka Therapeutics Inc
Biotechnology
Oruka Therapeutics Inc (ORKA) Stock News
The latest ORKA headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Oruka Therapeutics reported positive Week 28 interim data from its EVERLAST-A Phase 2a trial of ORKA-001, an IL-23p19 monoclonal antibody for plaque psoriasis. The drug demonstrated deepening clinical responses with 71.4% of patients achieving PASI 100 (complete skin clearance) and 87.3% achieving PASI 90, six months after the last dose with no additional dosing beyond Week 4. The drug maintained a favorable safety profile consistent with the IL-23 class. Full 52-week data is expected in December 2026.
- The Motley Fool·Neutral
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
Carl Dambkowski, Director of Oruka Therapeutics, sold 105,000 shares worth approximately $6.19 million on May 21, 2026, reducing his direct holdings by 58.74%. Despite the significant sale, Dambkowski retains approximately 73,743 shares and derivative securities. The sale was executed through the exercise and immediate sale of vested options. Oruka, a clinical-stage biotech company developing monoclonal antibody therapeutics, has seen its stock surge 407% over the past 12 months following positive clinical trial results for its lead candidate ORKA-001 in psoriasis treatment.